Key Interviews & Data Out of ASCO (AVAN, PFE, CELG, IMCL, DNA)
Today we saw many stocks with key news events at the annual American Society of Clinical Oncology or “ASCO” conference in Chicago. Much of the data had been signaled a couple of weeks ago ahead of the...
View ArticleShort Sellers Lighten Up on Major Biotechs in May
We ran the short selling report that just came out on major NASDAQ biotech stocks to see what the change in short selling was. Interestingly enough, in almost all of the major and large US biotechs...
View ArticleImClone Systems Starts Solid Malignancies & Lymphoma Trial Enrollment (IMCL)
ImClone Systems Inc. (NASDAQ: IMCL) has announced that its Phase 1 clinical trial of IMC-A12, itss fully human IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody plus the mTOR...
View ArticleMed-Bio Analyst Upgrades & Downgrades (BMY, EHTH, IMCL, BABY, NUVA, ONXX,...
These are some of the analyst calls that have been seen in medical and biotech this Friday morning: Bristol-Myers (NYSE: BMY) raised to Outperform at Bernstein. EHealth (NASDAQ: EHTH) Raised to...
View ArticleERBITUX Approved in Japan for Colorectal Cancer
ImClone Systems Incorporated (NASDAQ: IMCL) is seeing a slight gain this morning after the company announced that ERBITUX(R) has received final marketing authorization in Japan to treat patients with...
View ArticleMedical & Biotech Analyst Upgrades & Downgrades
Omnicare (OCR) Raised to Buy at Jefferies. RehabCare (RHB) Raised to Outperform at Morgan Keegan. Hansen Medical (HNSN) Cut to Neutral at Merriman Curhan Ford. ImClone (IMCL) Cut to Hold at Citigroup....
View ArticleMajor Biotechs on the Move (OSIP, DNA, IMCL, LLY, BMY, CRXX)
There is suddenly quite a bit going on in the land of biotech and drug stocks. We have a higher merger, a disappointing “add-on” possibility out of the magical Avastin, and an outright biotech...
View Article
